Triple anti-TNF-α therapy in early sepsis: A preliminary report

Journal of International Medical Research

Volumn 25, Issue 2, 1997, Pages 112-116

  Schattner, A ^a,b   El Hador, I ^a   Hahn, T ^b   Landau, Z ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Colchicine; Dexamethasone; Pentoxifylline; Sepsis; Tumour necrosis factor alpha

Indexed keywords

ANTIBIOTIC AGENT; COLCHICINE; DEXAMETHASONE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; SEPSIS;

EID: 0030892648     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059702500209     Document Type: Article

References (18)

1. Wenzel RP, Pinsky MR, Ulevitch RJ, et al: Current understanding of sepsis. Clin Infect Dis 1996; 22: 407 - 413.
2. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470 - 474.
3. Tracey KJ, Fong Y, Hesse DG, et al: Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330: 662 - 664.
4. Tracey KJ, Vlassara H, Cerami A, et al: Cachectin/tumour necrosis factor. Lancet 1989; i: 1122 - 1126.
5. Schimmer BB, Parker KL: Adrenocorticotropic hormones; adrenocortical steroids and their synthetic analogs. In: Hardman JG, et al. eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, (Hardman JG et al, eds) New York: McGraw Hill, 1996; pp 1459 - 1486.
6. Han J, Thompson P, Beutler B, et al: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/ tumour necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391 - 394.
7. Kremsner PG, Grundmann H, Neifer S, et al: Pentoxifylline prevents murine cerebral malaria. J Infect Dis 1991; 164: 605 - 608.
8. Lundblad R, Ekstrom P, Giercksy KE: Pentoxifylline improves survival and reduces tumour necrosis factor, interleukin-6 and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 1995; 3: 210 - 215.
9. Ding AH, Porteu F, Sanchez E, et al: Down regulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents. J Exp Med 1990; 171: 715 - 727.
10. Allen JN, Herzyk DJ, Wewers MD: Colchicine has opposite effects on interleukin-1 beta and tumor necrosis factoralpha production. Am J Physiol 1991; 261: L315 - 321.
11. Tiegs G, Freudenberg MA, Galanos C, et al: Colchicine prevents tumor necrosis factor-induced toxicity in vivo. Infect Immun 1992; 60: 1941 - 1945.
12. Naess F, Waage A, Roeise O, et al: Effects of a combined drug regimen on tumour necrosis factor and plasma kallikrein activity in experimental endotoxaemia. Eur J Surg 1994; 160: 77 - 86.
13. Schattner A, Lachmi M, Livneh A, et al: Tumor necrosis factor in familial Mediterranean fever. Am J Med 1991; 90: 434 - 438.
14. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771 - 778.
15. Dinarello CA, Gelfand JA, Wolff SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269: 1829 - 1835.
16. Lefering R, Neugebauer EA: Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23: 1294 - 1303.
17. Hinshaw LB, Beller-Todd BK, Archer LT: Current management of the septic shock patient: experimental basis for treatment. Circ Shock 1982; 9: 543 - 553.
18. Rice GC, Brown PA, Nelson RJ, et al: Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci USA 1994; 91: 3857 - 3861.